VOQUEZNA offers the power of more complete all‑day and all‑night heartburn‑free days vs placebo in Non‑Erosive GERD1
Heartburn relief through Week 4
PRIMARY ENDPOINT: MEAN PERCENTAGE (%)
OF 24-HOUR HEARTBURN-FREE DAYS1
OF 24-HOUR HEARTBURN-FREE DAYS1
Significantly more 24‑hour heartburn-free days through Week 4 vs placebo
*p-value from general linear model with treatment group as a factor and severity and frequency of heartburn at baseline as covariates.2
†Represents ITT population.
MEDIAN PERCENTAGE (%) OF 24-HOUR HEARTBURN-FREE DAYS1
†Represents ITT population.
Percentage of heartburn-free days and nights through Week 42,‡
EXPLORATORY ENDPOINT: HEARTBURN-FREE DAYS2,‡
†Represents ITT population.
‡No multiplicity adjustment was performed; therefore, no formal statistical conclusions should be made.2
EXPLORATORY ENDPOINT: % HEARTBURN-FREE NIGHTS2,‡
†Represents ITT population.
‡No multiplicity adjustment was performed; therefore, no formal statistical conclusions should be made.2
Rescue OTC antacid use
SECONDARY ENDPOINT: Percentage of days without rescue antacid use (gelusil)
during 4-week treatment period2
†Represents ITT population.
Observed 24-hour heartburn data over 6 months2
% OF PATIENTS WITH 24-HOUR HEARTBURN-FREE DAYS2
§Exploratory endpoint evaluating patient-reported outcomes. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.2
After 4 weeks of placebo-controlled treatment, the treatment effect of VOQUEZNA was evaluated in the 20‑week extension phase without placebo.2